Invention Application
- Patent Title: CHIMERIC ANTIGEN RECEPTOR-MODIFIED CELLS FOR THE TREATMENT OF CLDN6 EXPRESSING CANCER
-
Application No.: US18717782Application Date: 2022-12-08
-
Publication No.: US20250025505A1Publication Date: 2025-01-23
- Inventor: Ugur SAHIN , Petra OEHM , Benjamin RENGSTL , Katharina REINHARD , Liane Monika PREUSSNER , Özlem TÜRECI
- Applicant: BioNTech SE
- Applicant Address: DE Mainz
- Assignee: BioNTech SE
- Current Assignee: BioNTech SE
- Current Assignee Address: DE Mainz
- Priority: WOPCT/EP2021/085063 20211209,WOPCT/EP2022/074408 20220901
- International Application: PCT/EP2022/085072 WO 20221208
- Main IPC: A61K35/17
- IPC: A61K35/17 ; A61K9/127 ; A61K9/51 ; A61K31/7105 ; A61K39/00 ; A61K45/06 ; A61P35/00 ; C07K16/28 ; C12N5/0783
Abstract:
The present disclosure relates to chimeric antigen receptor (CAR) expressing immune effector cells showing highly specific and sensitive recognition of CLDN6 expressing cancer cells as well as a high potential for treating cancer in humans.
Information query
IPC分类:
